Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
13 mai 2024 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that the JCAD published an evaluation of formulation ingredients of ZORYVE (roflumilast) topical foam, 0.3%.
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
28 févr. 2024 16h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis and Sato today announced that the companies have entered into a strategic collaboration and licensing agreement for topical roflumilast in Japan.
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
14 janv. 2024 04h00 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced a new subgroup analysis in adults and adolescents with seborrheic dermatitis from STRATUM study
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
19 sept. 2023 07h30 HE
|
Arcutis Biotherapeutics, Inc.
Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trialsFor the primary endpoint, 25.4% of children...
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
10 août 2023 08h16 HE
|
Arcutis Biotherapeutics, Inc.
Arcutis to receive $30 million upfront payment and is eligible to receive potential development and commercial milestone payments, as well as double digit tiered royalties WESTLAKE VILLAGE,...
New Data from Arcutis’ Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Venereology (EADV) Congress
06 sept. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in...
Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis
04 oct. 2021 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Plaque psoriasis is a skin disease that affects approximately 8.6 million individuals in the U.S. and presents particular treatment challenges in certain anatomical regions.Roflumilast cream, a...
New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress
30 sept. 2021 08h30 HE
|
Arcutis Biotherapeutics, Inc.
Topical roflumilast provided significant improvements in severity and burden of itch in Phase 3 plaque psoriasis studies, as well as Phase 2 studies in seborrheic dermatitis and scalp and body...
Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent
28 sept. 2021 16h05 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...